搜索
 > 【Carbonic Anhydrase IX】重组蛋白信息

Carbonic Anhydrase IX信息

英文名称:Carbonic anhydrase IX
中文名称:碳酸酐酶IX
靶点别称:Membrane antigen MN,CAIX,Carbonic anhydrase IX,P54/58N,pMW1,MN,Carbonate dehydratase IX,G250 ,Carbonic anhydrase 9,Renal cell carcinoma-associated antigen G250,RCC-associated antigen G250,CA9,CA-IX
上市药物数量:0
临床药物数量:11
最高研发阶段:临床二期

Carbonic Anhydrase IX产品列表

货号 物种 产品描述 蛋白结构 纯度 活性
CA9-H5220
Human
Human Carbonic Anhydrase IX / CA9 (38-414) Protein
CA9-H5226
Human
Human Carbonic Anhydrase IX / CA9 (38-414) Protein, His Tag

Carbonic Anhydrase IX 分子别名

CAIX,CA9,CA-IX,G250,MN,P54/58N,pMW1

Carbonic Anhydrase IX 分子背景

Carbonic anhydrases (CAs) are a large family of zinc metalloenzymes. CAs form a family of enzymes that catalyze the rapid interconversion of carbon dioxide and water to bicarbonate and protons (or vice versa), a reversible reaction that occurs rather slowly in the absence of a catalyst. One of the functions of the enzyme in animals is to interconvert carbon dioxide and bicarbonate to maintain acid-base balance in blood and other tissues, and to help transport carbon dioxide out of tissues. The active site of most carbonic anhydrases contains a zinc ion. There are at least five distinct CA families (α, β, γ, δ and ε). Carbonic anhydrase 9 (CA9 / CAIX) is also known as Membrane antigen MN (MN), Renal cell carcinoma-associated antigen G250, which belongs to the alpha-carbonic anhydrase family. CA9 / CAIX with an optimal activity at pH 6.49. Reversible hydration of carbon dioxide. CA IX participates in pH regulation. CA9 may be involved in the control of cell proliferation and transformation. CA-IX appears to be a novel specific biomarker for a cervical neoplasia.

Carbonic Anhydrase IX 参考文献

Carbonic Anhydrase IX临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
Monoclonal antibody G250RIT 临床二期 杨森, Wilex 肾癌, 胆道癌
Lutetium-177 DOTA girentuximab 临床二期 Telix Pharmaceuticals, Wilex, Heidelberg 肾透明细胞癌 详情
Indium-111-DOTA-girentuximab-IRDye800CW (Radboud University) 临床一期 拉德堡德大学 肾细胞癌, 诊断试剂 详情
99mTc-MIP-1490 (Molecular Insight Pharmaceuticals) 99mTc-MIP-1490 临床阶段不明 Progenics Pharmaceutical 癌症
99mTc-MIP-1504 (Molecular Insight Pharmaceuticals) 99mTc-MIP-1504 临床阶段不明 Progenics Pharmaceutical 癌症
G250-scFV-transduced autologous T-lymphocyte cell therapy (Daniel den Hoed Cancer Center) 临床二期 伊拉斯姆斯大学 肾细胞癌
[90Y]-DOTA-cG250 临床一期 路德维格癌症研究所, 斯隆-凯特琳癌症中心 肾癌
Sulfamide-nitroimidazole 临床阶段不明 DualTPharma 癌症
BAY 794620 临床一期 拜耳 实体瘤 详情
DC-Ad-GMCAIX 临床一期 加州大学洛杉矶分校, Kite Pharma 肾细胞癌 详情
99mTc-MIP-1486 (Molecular Insight Pharmaceuticals) 临床阶段不明 Progenics Pharmaceutical 癌症

消息提示

请输入您的联系方式,再点击提交!

确定